CareValidate expanded its HRT offering for telehealth companies, combining hormone therapy with provider access, pharmacy services and AI-powered care coordination. The post CareValidate Launches Expanded HRT Offering appeared first on MedCity News.

Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair. The post Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science appeared first on MedCity News.

The MATCH IT Act aims to reduce patient matching errors. But a model used by vital records systems could provide a better solution. The post Congress’s Patient Matching Fix Won’t Work — Here’s What Would appeared first on MedCity News.

In most organizations the default access model was built for patient care, not for protecting colleagues. A nurse on another unit, a resident who rotated with them, a department administrator: any of them may technically be able to open the record, even when policy says they should not. The post Physician Mental Health and Health System Privacy: Why Doctors Avoid Their Own EHR appeared first on MedCity News.

Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response. The post Fractyl’s Weight Maintenance Device Meets Clinical Goal, but Shares Nosedive, Layoffs Follow appeared first on MedCity News.

MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health. The post Where Are the Biggest Opportunities in Women’s Cardiovascular Health? appeared first on MedCity News.

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD. The post Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill appeared first on MedCity News.

Ultimately, while clinical training teaches nurses how to care for patients within a system, business education empowers them to design, protect, and scale the system. The post Why an Independent NP Practice Requires an Undergraduate Business Foundation appeared first on MedCity News.

Amazon, Axon Enterprise, Google, Meta and Oracle backed expanding electronic prior authorization to self-funded employer health plans. The post Amazon, Google and Other Major Employers Back CMS Prior Auth Effort appeared first on MedCity News.

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a majority stake in Aurion Biotech, a startup developing a corneal cell therapy. The post Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition appeared first on MedCity News.

Throwing more money at SDoH programs isn’t going to magically fix them. Instead, plans should be focusing on building out these three specific capabilities that, together, can noticeably alter the playing field. The post Why SDoH Programs Fall Short — and What It Takes to Make Them Work appeared first on MedCity News.

In addition to a packed conference agenda and tours of the Pegasus Park healthcare and life science innovation hub in Dallas, INVEST Digital Health also includes an innovation showcase with novel health tech and medtech offerings as well as networking opportunities. The post INVEST Digital Health Celebrates Healthcare Innovation in Texas appeared first on MedCity News.

Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration. The post Judi Health Launches Medicare Part D Plan for Employers appeared first on MedCity News.

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure appeared first on MedCity News.

As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational question: Who is responsible for ensuring that these tools remain safe once they enter clinical practice? The post AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation appeared first on MedCity News.